published meta-analysis   sensitivity analysis   studies

antiviral and associated therapy in infections other than COVID-19 - Summary of results

OutcomeTE95% CInkI2ROBPub. bias clinical improvementdetailed resultsBorges, 2013 30.82 [1.78; 534.26] Tricou, 2010 0.80 [0.61; 1.04] 3.72[0.11; 127.58]Borges, 2013, Tricou, 2010284%683lownot evaluable Influenza-like infectiondetailed resultsPaton, 2011 1.54 [0.62; 3.78] 1.54[0.62; 3.78]Paton, 201110%1,462NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-04-26 13:30 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 92 - treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814 - roots T: 290